Noltec — Competitive Intelligence Brief

Noltec (ILAPRAZOLE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Proton Pump Inhibitors. Area: Gastroenterology.

marketed Proton Pump Inhibitors Potassium-transporting ATPase Gastroenterology Small molecule

Target snapshot

Noltec (ILAPRAZOLE).

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Noltec TARGET	ILAPRAZOLE		marketed	Proton Pump Inhibitors	Potassium-transporting ATPase
Nexium	esomeprazole	AstraZeneca	marketed	Proton pump inhibitor (PPI)	Potassium-transporting ATPase	2001-02-20
Aciphex	rabeprazole	Waylis	marketed	Proton Pump Inhibitor	Potassium-transporting ATPase	1999-01-01
Digicor	DIGITOXIN	Eli Lilly	marketed	digitoxin	Signal transducer and activator of transcription 3, Potassium voltage-gated channel subfamily H member 2, Sodium/potassium-transporting ATPase subunit alpha-1	1982-01-01
Cedilanid D	DESLANOSIDE	Novartis	marketed	deslanoside	Sodium/potassium-transporting ATPase	1982-01-01
Acylanid	ACETYLDIGITOXIN	Novartis	marketed	acetyldigitoxin	Sodium/potassium-transporting ATPase	1975-01-01
Dexilant	Dexilant	Genuine Research Center, Egypt	marketed		Sterile alpha and TIR motif-containing protein 1, Cytosolic endo-beta-N-acetylglucosaminidase, Potassium-transporting ATPase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Proton Pump Inhibitors class)

1. · 2 drugs in this class